These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34170549)

  • 1. Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis.
    Edén A; Simrén J; Price RW; Zetterberg H; Gisslén M
    J Neurochem; 2021 Oct; 159(1):61-77. PubMed ID: 34170549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series.
    Edén A; Kanberg N; Gostner J; Fuchs D; Hagberg L; Andersson LM; Lindh M; Price RW; Zetterberg H; Gisslén M
    Neurology; 2021 Jan; 96(2):e294-e300. PubMed ID: 33004602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients.
    Jarius S; Pache F; Körtvelyessy P; Jelčić I; Stettner M; Franciotta D; Keller E; Neumann B; Ringelstein M; Senel M; Regeniter A; Kalantzis R; Willms JF; Berthele A; Busch M; Capobianco M; Eisele A; Reichen I; Dersch R; Rauer S; Sandner K; Ayzenberg I; Gross CC; Hegen H; Khalil M; Kleiter I; Lenhard T; Haas J; Aktas O; Angstwurm K; Kleinschnitz C; Lewerenz J; Tumani H; Paul F; Stangel M; Ruprecht K; Wildemann B;
    J Neuroinflammation; 2022 Jan; 19(1):19. PubMed ID: 35057809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid in COVID-19: A systematic review of the literature.
    Lewis A; Frontera J; Placantonakis DG; Lighter J; Galetta S; Balcer L; Melmed KR
    J Neurol Sci; 2021 Feb; 421():117316. PubMed ID: 33561753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement.
    Senel M; Abu-Rumeileh S; Michel D; Garibashvili T; Althaus K; Kassubek J; Otto M
    Eur J Neurol; 2020 Nov; 27(11):2378-2380. PubMed ID: 32781484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development.
    Espíndola OM; Brandão CO; Gomes YCP; Siqueira M; Soares CN; Lima MASD; Leite ACCB; Torezani G; Araujo AQC; Silva MTT
    Int J Infect Dis; 2021 Jan; 102():155-162. PubMed ID: 33127503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients.
    DeKosky ST; Kochanek PM; Valadka AB; Clark RSB; Chou SH; Au AK; Horvat C; Jha RM; Mannix R; Wisniewski SR; Wintermark M; Rowell SE; Welch RD; Lewis L; House S; Tanzi RE; Smith DR; Vittor AY; Denslow ND; Davis MD; Glushakova OY; Hayes RL
    J Neurotrauma; 2021 Jan; 38(1):1-43. PubMed ID: 33115334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms.
    Edén A; Grahn A; Bremell D; Aghvanyan A; Bathala P; Fuchs D; Gostner J; Hagberg L; Kanberg N; Kanjananimmanont S; Lindh M; Misaghian S; Nilsson S; Schöll M; Sigal G; Stentoft E; Studahl M; Yilmaz A; Wang M; Stengelin M; Zetterberg H; Gisslén M
    JAMA Netw Open; 2022 May; 5(5):e2213253. PubMed ID: 35604688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted metabolomics identifies accurate CSF metabolite biomarkers for the differentiation between COVID-19 with neurological involvement and CNS infections with neurotropic viral pathogens.
    Neu F; Nay S; Schuchardt S; Klawonn F; Skripuletz T; Suehs KW; Pessler F
    J Transl Med; 2024 Jul; 22(1):620. PubMed ID: 38961383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients.
    Alexopoulos H; Magira E; Bitzogli K; Kafasi N; Vlachoyiannopoulos P; Tzioufas A; Kotanidou A; Dalakas MC
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32978291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in the Serum and Cerebrospinal Fluid of Patients With Coronavirus Disease 2019 and Neurological Symptoms.
    Cunningham JL; Virhammar J; Rönnberg B; Dopico XC; Kolstad L; Albinsson B; Kumlien E; Nääs A; Klang A; Westman G; Zetterberg H; Frithiof R; Lundkvist Å; Karlsson Hedestam GB; Rostami E
    J Infect Dis; 2022 Mar; 225(6):965-970. PubMed ID: 33744954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Systematic Review of CSF analysis that defines Neurological Manifestations of COVID-19.
    Tandon M; Kataria S; Patel J; Mehta TR; Daimee M; Patel V; Prasad A; Chowdhary AA; Jaiswal S; Sriwastava S
    Int J Infect Dis; 2021 Mar; 104():390-397. PubMed ID: 33434662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients.
    Yachou Y; El Idrissi A; Belapasov V; Ait Benali S
    Neurol Sci; 2020 Oct; 41(10):2657-2669. PubMed ID: 32725449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients.
    Lersy F; Benotmane I; Helms J; Collange O; Schenck M; Brisset JC; Chammas A; Willaume T; Lefebvre N; Solis M; Hansmann Y; Fabacher T; Caillard S; Mertes PM; Pottecher J; Schneider F; Meziani F; Fafi-Kremer S; Kremer S
    J Infect Dis; 2021 Feb; 223(4):600-609. PubMed ID: 33249438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients.
    Guilmot A; Maldonado Slootjes S; Sellimi A; Bronchain M; Hanseeuw B; Belkhir L; Yombi JC; De Greef J; Pothen L; Yildiz H; Duprez T; Fillée C; Anantharajah A; Capes A; Hantson P; Jacquerye P; Raymackers JM; London F; El Sankari S; Ivanoiu A; Maggi P; van Pesch V
    J Neurol; 2021 Mar; 268(3):751-757. PubMed ID: 32734353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms.
    Zhou Z; Kang H; Li S; Zhao X
    J Neurol; 2020 Aug; 267(8):2179-2184. PubMed ID: 32458193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What can cerebrospinal fluid testing and brain autopsies tell us about viral neuroinvasion of SARS-CoV-2.
    Li YC; Zhang Y; Tan BH
    J Med Virol; 2021 Jul; 93(7):4247-4257. PubMed ID: 33724490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encephalitic syndrome and anosmia in COVID-19: Do these clinical presentations really reflect SARS-CoV-2 neurotropism? A theory based on the review of 25 COVID-19 cases.
    Pouga L
    J Med Virol; 2021 Jan; 93(1):550-558. PubMed ID: 32672843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings.
    Guerrero JI; Barragán LA; Martínez JD; Montoya JP; Peña A; Sobrino FE; Tovar-Spinoza Z; Ghotme KA
    BMC Infect Dis; 2021 Jun; 21(1):515. PubMed ID: 34078305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid.
    Heming M; Li X; Räuber S; Mausberg AK; Börsch AL; Hartlehnert M; Singhal A; Lu IN; Fleischer M; Szepanowski F; Witzke O; Brenner T; Dittmer U; Yosef N; Kleinschnitz C; Wiendl H; Stettner M; Meyer Zu Hörste G
    Immunity; 2021 Jan; 54(1):164-175.e6. PubMed ID: 33382973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.